This cytokine downregulates, at the surface of natural killer (NK) cells, CD8+ cytolytic T cells and γδ T cells, the expression of the NKG2D activating receptor, which in turn cannot interact with the NKG2D ligands expressed by tumor cells. The gene discussed is CD8A; the disease is neoplasm.